October 2020
We can make COVID-19 vaccines rapidly available only if we have rigorous evidence—which is threatened if we allow emerging data from candidate trials to be disclosed in ways that might influence trial design or conduct and potentially bias the results, write Susan Ellenberg, PhD, and colleagues.